November 2017 Investor Presentation Webcast
Author: Anteo Diagnostics Ltd Date Posted:6 November 2017
Anteo Diagnostics Ltd (ASX:ADO) ("Anteo" or the "Company") is pleased to host a live webcast to discuss the Company's strategy with investors.
Executive Chairman, Dr John Hurrell, will update investors and take questions on:
- The challenges of the last 12 months
- Strategy of the Company
- Goals of the Company
- Update on opportunities
- Board structure
A brief investor presentation will be made during the webcast prior to question time.
|Time:||Monday 6 November 2017, 3:00pm (AEDT)|
|Webcast Link (replay):||VIEW WEBCAST|
A copy of the presentation slides and a transcript of the have been made available below.
The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information.
The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.
Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.
This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.